May 18, 2020 / 2:14 AM / 18 days ago

BRIEF-Cansino Biologics Got Clinical Trial Application Approval For Recombinant Novel Coronavirus Vaccine

May 18 (Reuters) - Cansino Biologics Inc:

* GOT CLINICAL TRIAL APPLICATION APPROVAL FOR RECOMBINANT NOVEL CORONAVIRUS VACCINE (ADENOVIRUS TYPE 5 VECTOR) FROM HEALTH CANADA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below